# Title

 Food and Drugs. PART 54â€”FINANCIAL DISCLOSURE BY CLINICAL INVESTIGATORS


# ID

 CFR-2018-title21-vol1.Pt. 54


# Structured Analysis Summary

| Type        | Values                                                                       |
|:------------|:-----------------------------------------------------------------------------|
| Money       | [(50000.0, 'USD'), (25000.0, 'USD')]                                         |
| Constraints | ['greater', 'more than', 'less than', 'after', 'exceeds']                    |
| Duration    | ['2.0 year', '1.0 year']                                                     |
| Condition   | ['where', 'if', 'subject to']                                                |
| Entities    | ['Scope', 'Clinical', 'Agency', 'Food', 'Certification', 'Study', 'Purpose'] |


# Structured Analysis With Context

 


## Money

| Money            | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-----------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (50000.0, 'USD') | (b) Significant equity interest in the sponsor of a covered study means any ownership interest, stock options, or other financial interest whose value cannot be readily determined through reference to public prices (generally, interests in a nonpublicly traded corporation), or any equity interest in a publicly traded corporation that exceeds $50,000 during the time the clinical investigator is carrying out the study and for 1 year following completion of the study.                                                                                           |
| (25000.0, 'USD') | (f) Significant payments of other sorts means payments made by the sponsor of a covered study to the investigator or the institution to support activities of the investigator that have a monetary value of more than $25,000, exclusive of the costs of conducting the clinical study or other clinical studies, (e.g., a grant to fund ongoing research, compensation in the form of equipment or retainers for ongoing consultation or honoraria) during the time the clinical investigator is carrying out the study and for 1 year following the completion of the study. |


## Constraints

| Constraints   | Context                                                                                                            |
|:--------------|:-------------------------------------------------------------------------------------------------------------------|
| greater       | unfavorable outcome, such as compensation that is explicitly greater for a favorable result or compensation to the |
| exceeds       | equity interest in a publicly traded corporation that exceeds $50,000 during the time the clinical investigator is |
| more than     | the investigator that have a monetary value of more than $25,000, exclusive of the costs of conducting the         |
| less than     | (2) If the certification covers  less than all covered clinical data in the application, the                       |
| after         | paragraph (a) of this section for 2 years after  the date of approval of the application.                          |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.0 year   | (b) Significant equity interest in the sponsor of a covered study means any ownership interest, stock options, or other financial interest whose value cannot be readily determined through reference to public prices (generally, interests in a nonpublicly traded corporation), or any equity interest in a publicly traded corporation that exceeds $50,000 during the time the clinical investigator is carrying out the study and for 1 year following completion of the study.                                                                                           |
| 1.0 year   | (f) Significant payments of other sorts means payments made by the sponsor of a covered study to the investigator or the institution to support activities of the investigator that have a monetary value of more than $25,000, exclusive of the costs of conducting the clinical study or other clinical studies, (e.g., a grant to fund ongoing research, compensation in the form of equipment or retainers for ongoing consultation or honoraria) during the time the clinical investigator is carrying out the study and for 1 year following the completion of the study. |
| 1.0 year   | The investigator shall promptly update this information if any relevant changes occur in the course of the investigation or for 1 year following completion of the study.                                                                                                                                                                                                                                                                                                                                                                                                       |
| 2.0 year   | (1) For any application submitted for a covered product, an applicant shall retain records as described in paragraph (a) of this section for 2 years after the date of approval of the application.                                                                                                                                                                                                                                                                                                                                                                             |


## Condition

| Condition   | Context                                                                                                                 |
|:------------|:------------------------------------------------------------------------------------------------------------------------|
| if          | consider clinical studies inadequate and the data inadequate if , among other things, appropriate steps have not        |
| subject to  | submitted in a marketing application or reclassification petition subject to this part that the applicant or FDA relies |
| where       | for making the appropriate certification or disclosure statement where the applicant either contracted with one or more |
| subject to  | Clinical investigators  subject to investigational new drug or investigational device exemption regulations             |
| if          | (2) If the cert if ication covers less than all covered clinical data                                                   |
| if          | The investigator shall promptly update this information  if any relevant changes occur in the course of                 |
| if          | potential increase in the value of the interest if the product is approved) and steps that have                         |


## Entities

| Entities      | Context                                                                       |
|:--------------|:------------------------------------------------------------------------------|
| Food          | Food  and Drugs.                                                              |
| Purpose       | Purpose .                                                                     |
| Scope         | Scope .                                                                       |
| Certification | Certification  and disclosure requirements.                                   |
| Clinical      | Clinical investigators subject to investigational new drug or investigational |
| Agency        | Agency  evaluation of financial interests.                                    |
| Study         | Study designs that utilize such approaches as multiple investigators          |


